(iv) indicate whether complainant, complainant's licensees, and/or third-party suppliers have the capacity to replace the volume of articles potentially subject to the recommended orders within a commercially reasonable time; and

(v) explain how the recommended orders would impact consumers in the United States.

Written submissions must be filed no later than by close of business on Monday, September 8, 2025.

Persons filing written submissions must file the original document electronically on or before the deadlines stated above pursuant to 19 CFR 210.4(f). Submissions should refer to the investigation number ("Inv. No. 337—TA—1428") in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, https://www.usitc.gov/secretary/fed\_reg\_notices/rules/handbook\_on\_electronic\_filing.pdf). Persons with questions regarding filing should contact the Secretary (202—205—2000).

Any person desiring to submit a document to the Commission in confidence must request confidential treatment by marking each document with a header indicating that the document contains confidential information. This marking will be deemed to satisfy the request procedure set forth in Rules 201.6(b) and 210.5(e)(2) (19 CFR 201.6(b) & 210.5(e)(2)). Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. Any non-party wishing to submit comments containing confidential information must serve those comments on the parties to the investigation pursuant to the applicable Administrative Protective Order. A redacted non-confidential version of the document must also be filed simultaneously with any confidential

filing and must be served in accordance with Commission Rule 210.4(f)(7)(ii)(A) (19 CFR 210.4(f)(7)(ii)(A)). All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this investigation may be disclosed to and used: (i) by the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements. All nonconfidential written submissions will be available for public inspection on EDIS.

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission. Issued: August 8, 2025.

#### Lisa Barton,

Secretary to the Commission.  $[ FR \ Doc. \ 2025-15304 \ Filed \ 8-11-25; \ 8:45 \ am]$   $\textbf{BILLING \ CODE \ 7020-02-P}$ 

### **DEPARTMENT OF JUSTICE**

Drug Enforcement Administration [Docket No. DEA-1584]

Bulk Manufacturer of Controlled Substances Application: Benuvia Operations, LLC

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Benuvia Operations, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 14, 2025. Such persons may also file a written request for a hearing on the application on or before October 14, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on June 13, 2025, Benuvia Operations, LLC, 3950 North Mays Street, Round Rock, Texas 78665, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Ibogaine	7260	ı
Marihuana Extract	7350	1
Tetrahydrocannabinols	7370	1
Mescaline	7381	1
3,4-Methylenedioxyamphetamine	7400	1
3.4-Methylenedioxymethamphetamine	7405	1
5-Methoxy-N,N-dimethyltryptamine	7431	1
Dimethyltryptamine	7435	1
Psilocybin	7437	1
Psilocyn	7438	1
5-Methoxy-N,N-diisopropyltryptamine	7439	1
Amphetamine	1100	II
Lisdexamfetamine	1205	II
Remifentanil	9739	II

The company plans to bulk manufacture the listed controlled substances for internal research and dosage formulation development. No other activities for these drug codes are authorized for this registration.

#### Justin Wood,

Acting Deputy Assistant Administrator.
[FR Doc. 2025–15279 Filed 8–11–25; 8:45 am]
BILLING CODE P

#### **DEPARTMENT OF LABOR**

# **Employee Benefits Security Administration**

[Prohibited Transaction Exemption 2025–07; Application No. D-12102]

Exemption for the Royal Bank of Canada and Its Current and Future Affiliates (Collectively, RBC or the Applicant) Located in Toronto, Ontario, Canada

**AGENCY:** Employee Benefits Security Administration, Labor.

**ACTION:** Notice of exemption.

**SUMMARY:** This document provides notice of an individual exemption from certain prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974 (ERISA) and the Internal Revenue Code of 1986 (the Code). This exemption permits certain qualified professional asset managers with specified relationships to Royal Bank of Canada Trust Company (Bahamas) Limited, and certain current and future affiliates of the Royal Bank of Canada (collectively, the RBC QPAMs), to continue to rely on the class exemptive relief granted in Prohibited Transaction Exemption (PTE) 84-14 (PTE 84-14 or the QPAM Exemption), notwithstanding the March 5, 2024 judgment of conviction against Royal Bank of Canada Trust Company (Bahamas) Limited (RBCTC Bahamas) for aiding and abetting tax fraud, entered in France in the Paris Court of Appeal.

**DATES:** This final exemption will be in effect for the period beginning on the earlier of September 5, 2025, or date of publication in the **Federal Register**; and end on March 4, 2030 (the Exemption Period).

FOR FURTHER INFORMATION CONTACT: Ms. Blessed Chuksorji-Keefe, Office of Exemption Determinations, Employee Benefits Security Administration, U.S. Department of Labor, (202) 693–8567 (this is not a toll-free number).

**SUPPLEMENTARY INFORMATION:** The Applicant requested an individual

exemption pursuant to ERISA section 408(a) and Code section 4975(c)(2) in accordance with the Department's exemption procedures. On January 17, 2025, the Department published a notice of proposed exemption (the Proposed Exemption) in the Federal Register that would permit the RBC QPAMs to rely on the QPAM Exemption for five years, notwithstanding the March 5, 2024 judgment of conviction against RBCTC Bahamas for aiding and abetting tax fraud.

After considering the public comment that the Department received in response to the Proposed Exemption, the Department is granting this exemption to protect the interests of participants and beneficiaries of plans that are subject to Part 4, Title I of ERISA (ERISA-covered plans) and Individual Retirement Accounts subject to Code Section 4975 (IRAs) (together, Covered Plans).<sup>4</sup> This exemption provides only the relief specified in the text of the exemption and does not provide relief from violations of any law other than the prohibited transaction provisions of Title I of ERISA and the Code expressly stated herein.

Based on the Applicant's adherence to all the conditions of PTE 2016-105 and this exemption, the Department makes the requisite findings under ERISA section 408(a) and Code section 4975(c)(2) that the exemption is: (1) administratively feasible for the Department; (2) in the interest of Covered Plans and their participants and beneficiaries; and (3) protective of the rights of the participants and beneficiaries of Covered Plans. Accordingly, affected parties should be aware that the conditions incorporated in this exemption are necessary, individually and taken as a whole, for the Department to grant the relief requested by the Applicant. Absent these conditions, the Department would not have granted this exemption.

Benefits of the Exemption: The Department's objective in granting this exemption is to protect Covered Plans from the harms and costs that RBC represents would be imposed on them if the RBC OPAMs could no longer rely on the relief provided in the QPAM Exemption. Among other important conditions, this exemption ensures that a Covered Plan can terminate its relationship with an RBC QPAM in an orderly and cost-effective fashion when the fiduciary of a Covered Plan determines that it is prudent to do so, subject to certain reasonable restrictions described herein. This exemption promotes the RBC QPAMs' adherence to basic fiduciary standards and responsibilities required by Title I of ERISA and the Code and reinforces their obligation to act with a high degree of integrity on behalf of their Covered Plan clients as required by the QPAM Exemption.

## **Background**

The Royal Bank of Canada

1. RBC is a Canadian corporation headquartered in Toronto, Ontario, Canada. RBC provides personal and commercial banking, wealth management services, insurance, investor services, and capital markets products and services on a global basis.

#### The RBC QPAMs

- 2. The primary U.S. bank and U.S. registered investment adviser affiliates in which RBC owns a significant interest, directly or indirectly, and that currently rely on the QPAM Exemption include the following:
- RBC Global Asset Management (U.S.) Inc. In its most recent (at the time of the April 3, 2024 exemption application) Form ADV Part I(A) reported assets of almost \$80 billion managed on a discretionary basis, including ERISA assets.
- RBC Global Asset Management (UK) Limited. As of April 2, 2024, managed assets of nearly \$122 billion on a discretionary basis, including ERISA assets and approximately \$993 million in public pension assets for state and local plans, which may by law or contract require it to comply with the prohibited transaction rules under ERISA.
- RBC Capital Markets, LLC. As of April 2, 2024, this entity managed assets of approximately \$149 billion on a discretionary basis, including ERISA and IRA assets.
- City National Bank. As of April 2, 2024, this entity managed assets of approximately \$24.2 billion on a discretionary basis, including ERISA and IRA assets.

<sup>&</sup>lt;sup>1</sup> 29 CFR part 2570, subpart B (75 FR 66637, 66644, October 27, 2011).

<sup>&</sup>lt;sup>2</sup> 90 FR 6013 (January 17, 2025).

<sup>&</sup>lt;sup>3</sup> 49 FR 9494 (March 13, 1984), as corrected at 50 FR 41430 (October 10, 1985), as amended at 70 FR 49305 (August 23, 2005), as amended at 75 FR 38837 (July 6, 2010), and as amended at 89 FR 23090 (April 3, 2024).

<sup>&</sup>lt;sup>4</sup>The term "Covered Plan" means an ERISA-covered Plan or an IRA, in each case, with respect to which an RBC QPAM relies on PTE 84–14, or with respect to which an RBC QPAM (or any RBC affiliate) has expressly represented that the manager qualifies as a QPAM or relies on the QPAM Exemption. A "Covered Plan" does not include an ERISA-covered Plan or IRA to the extent the RBC QPAM has expressly disclaimed reliance on QPAM status or PTE 84–14 in entering into its contract, arrangement, or agreement with the Covered Plan.

<sup>&</sup>lt;sup>5</sup>81 FR 75147 (October 28, 2016).